SecBot SecBot

BMRN drug pipeline

BIOMARIN PHARMACEUTICAL INC · 16 rated drugs
$57.99
+1.3% 1-day · Nov 16
Next catalyst
May 30, 2027
VOXZOGO PDUFA date · in 195 days
Typical move on FDA news
±1.2%
1-day, median of 8 events
IV rank
5
IV 31% · HV 29%
Rated drugs
16
1 bearish · 15 neutral
Phase 3 trials
3
0 with results posted

Upcoming catalysts

1 dated
  1. May 30, 2027195d
    VOXZOGO
    PDUFA date · Hypochondroplasia (HCH)

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2/3
Time to marketIf successful through Phase 2/3, potential launch is estimated around 2030 per earlier BioMarin guidance, though the timeline depends on Phase 2/3 results and regulatory interactions.

BMN 333 Updated Nov 2

What to watch

The next catalyst for BMN 333 is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given). Positive data would validate a weekly, potentially superior alternative to Voxzogo and strengthen BioMarin's achondroplasia franchise against Ascendis' newly approved Yuviwel. Negative or underwhelming data would raise doubts about the drug's best-in-class potential and could pressure BMRN shares given the competitive threat.

Bull case
  • Phase 1 data showed BMN 333 achieved >13x higher free CNP exposure versus another long-acting CNP agent, with favorable safety and no dose-limiting toxicities, supporting once-weekly dosing.
  • BioMarin management describes BMN 333 as a 'potential best-in-class molecule' with opportunity to drive greater improvements in growth parameters versus available therapies.
  • BMN 333 is designed as a weekly subcutaneous injection versus Voxzogo's daily injection, a significant convenience advantage that could drive patient and physician adoption.
Bear case
  • Ascendis Pharma's Yuviwel (navepegritide) was FDA-approved on February 27, 2026 as the first once-weekly CNP for achondroplasia, establishing a direct competitive head start while BMN 333 is still in Phase 2/3 trials.
  • BMN 333 is years from potential approval (estimated launch around 2030 per earlier BioMarin guidance), giving competitors time to capture market share.
  • The Phase 2/3 trial is active-controlled against BioMarin's own Voxzogo, creating a high bar: the drug must demonstrate superiority or at least non-inferiority with less frequent dosing to justify switching.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since 2017 (FDA) and 2017 (EMA).

BRINEURA cerliponase alfa Updated Nov 2

What to watch

BRINEURA is a mature, approved product with no pending regulatory catalyst. Watch BioMarin's quarterly enzyme-therapy revenue reports for organic growth trends, and monitor the April 2029 orphan-drug exclusivity expiry for potential biosimilar or competitive threats. The drug's contribution to BMRN's overall thesis is modest relative to larger growth drivers like VOXZOGO and the recently acquired Amicus portfolio.

Bull case
  • First and only FDA-approved treatment for CLN2 disease (Batten disease), with no direct competitors on the market.
  • Label expanded in July 2024 to cover children of all ages (previously 3+), broadening the addressable patient population.
  • Enzyme replacement therapy with a well-established mechanism; revenue grew in Q1 2026 as part of BioMarin's Enzyme Therapies segment (up 6% Y/Y).
Bear case
  • Ultra-rare indication (CLN2 disease) limits peak revenue potential; reported ~$186M in 2025, a modest contributor to BioMarin's ~$3.85B projected 2026 revenue.
  • Orphan-drug exclusivity is projected to expire around April 2029, opening the door to biosimilar or competitive entry in a few years.
  • Intraventricular administration via surgically implanted catheter is invasive and may limit patient uptake versus less invasive future alternatives.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval August 2018).

GALAFOLD migalastat Updated Nov 2

What to watch

Galafold has no near-term binary catalyst; the next event to watch is the ongoing Phase 3b pediatric trial (NCT06904261), which could support a label expansion to children aged 2-12, but that readout is likely 12+ months away. For BMRN stock, the next catalysts are broader: Q4 2026 earnings (February 2027) and progress of the newly licensed Fabry ERT (HM15421/GC1134A) into the clinic.

Bull case
  • Galafold is the only oral monotherapy for Fabry disease, offering a convenience advantage over IV enzyme replacement therapies that require bi-weekly infusions.
  • Revenue is growing: $521.7M in full-year 2025 (up 14% YoY) and $152M in Q3 2026 alone (first full quarter under BioMarin), contributing to BioMarin's record $1.025B quarterly revenue.
  • Strong patent protection with 66 US patents and estimated generic entry not until 2037-2042, providing long commercial exclusivity.
Bear case
  • Galafold faces competition from established IV enzyme replacement therapies (Sanofi's Fabrazyme, Takeda's Replagal, Chiesi's Elfabrio) and emerging gene therapies and substrate reduction therapies in the Fabry pipeline.
  • The drug is only effective for patients with amenable GLA gene variants, which limits its addressable patient population to roughly 35-50% of Fabry patients.
  • Patent challenges from Teva (settled for 2037 entry) and Aurobindo create long-term generic overhang, though near-term risk is low.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2005.

NAGLAZYME galsulfase Updated Nov 2

What to watch

NAGLAZYME is a mature, approved product with no pending binary catalysts. The next meaningful event for BioMarin overall is the Q4 2026 earnings report (late February 2027), where NAGLAZYME's steady-state revenue trajectory and any biosimilar entry updates will be visible. For this specific drug, watch for any biosimilar development announcements or label updates, but neither is currently scheduled.

Bull case
  • NAGLAZYME remains the first and only FDA-approved enzyme replacement therapy for MPS VI (Maroteaux-Lamy syndrome), a rare, life-threatening genetic disorder with no other approved treatment options (source: FDA label and BioMarin press release).
  • The drug generated $485.4 million in 2025 revenue, a meaningful and steady contributor to BioMarin's enzyme therapies franchise, which grew 6% year-over-year in Q1 2026 (source: BioMarin Q1 2026 press release, TradingView 10-K analysis).
  • No biosimilar competitor has entered the market despite expired exclusivity, suggesting high barriers to entry for a complex biologic enzyme replacement therapy serving a very small patient population (source: Synapse/Patsnap analysis).
Bear case
  • NAGLAZYME revenue declined 11.5% year-over-year in Q3 2026 to $108 million, driven by timing of large international orders, showing lumpiness in a small-market product.
  • Patent and regulatory exclusivity have expired (projected loss of exclusivity around 2017 per CliffBio), leaving the drug exposed to eventual biosimilar competition, though none has entered to date (source: DrugPatentWatch).
  • NAGLAZYME is a small part of BioMarin's now-diversified portfolio (post-Amicus acquisition), limiting its individual impact on the stock. BioMarin's 2025 total revenue was $3.2 billion, with NAGLAZYME contributing $485.4 million or about 15% (source: TradingView 10-K analysis).
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approved September 28, 2023; EMA approved).

OPFOLDA miglustat Updated Nov 2

What to watch

OPFOLDA (as part of POMBILITI + OPFOLDA) is already approved and generating revenue for BioMarin. The next catalyst to watch is the commercial ramp: quarterly revenue growth and market share gains against Sanofi's Nexviazyme in the Pompe disease market. BioMarin's Q3 2026 earnings (reported Nov 2, 2026) showed POMBILITI + OPFOLDA benefiting from supply constraints on competing therapies, but full-year guidance was trimmed slightly. No binary regulatory catalyst is scheduled.

Bull case
  • OPFOLDA (miglustat) is part of a two-component therapy (with POMBILITI) that is FDA-approved and EMA-approved for late-onset Pompe disease, a rare, life-threatening disorder with limited treatment options and a growing market estimated at $2.04 billion in 2026.
  • Five-year Phase 3 open-label extension data presented at WMS October 2026 showed durable long-term efficacy: ERT-naive patients improved six-minute walk distance by +10.5% at year 5, and ERT-experienced patients stabilized (+0.7%), reinforcing the drug's long-term value proposition.
  • BioMarin acquired Amicus Therapeutics for $4.8 billion (completed April 27, 2026), adding POMBILITI + OPFOLDA and GALAFOLD. Q3 2026 was the first quarter with a full contribution: total revenue hit $1.025 billion (up 32% YoY), with Metabolic Conditions revenue up 44% YoY driven by these additions.
Bear case
  • OPFOLDA faces direct competition from Sanofi's Nexviazyme (avalglucosidase alfa), which has a broader approved age range and is also indicated for late-onset Pompe disease, creating a market share battle.
  • Five-year Phase 3 extension data showed only a +0.7% change in six-minute walk distance for ERT-experienced patients at year 5, suggesting the drug stabilizes rather than improves function in patients who have already been on other enzyme replacement therapy.
  • BioMarin lowered its full-year 2026 revenue guidance to $3.8-$3.9 billion (from prior expectations), citing roughly $70 million in deferred international orders, which may signal lumpy adoption.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. (since 2018 for adults, expanded to adolescents 12+ in February 2026) and in the EU (since 2019 for ages 16+, with a May 2026 CHMP positive opinion for further expansion).

PALYNZIQ pegvaliase-pqpz Updated Nov 2

What to watch

PALYNZIQ has no upcoming binary catalyst; the next major BioMarin catalysts are VOXZOGO PDUFA dates (Feb 28, 2027 for full achondroplasia approval, May 30, 2027 for hypochondroplasia). Watch Q4 2026 earnings for PALYNZIQ's post-adolescent-expansion revenue trajectory and any EMA adolescent label decision for Europe.

Bull case
  • PALYNZIQ is the only FDA-approved enzyme substitution therapy for PKU, with no direct competitors in its class, giving it a unique position in a growing market.
  • The February 2026 FDA approval for adolescents aged 12+ expanded the addressable patient population significantly, and the company expects full-year 2026 PALYNZIQ revenue to increase year-over-year.
  • PALYNZIQ delivered $135M in Q2 2026 revenue, up 27% year-over-year, and patient numbers grew across all BioMarin metabolic therapies.
Bear case
  • PALYNZIQ carries an FDA black-box warning for anaphylaxis, which may occur at any time during treatment, limiting patient uptake and requiring supervised administration.
  • The drug is an injectable enzyme therapy requiring daily injections, which creates a compliance hurdle versus oral alternatives like Kuvan (sapropterin) and pipeline oral candidates such as sepiapterin and JNT-517.
  • BioMarin's Q3 2026 GAAP net loss widened to -$123M, and full-year 2026 Non-GAAP EPS guidance was slashed ~40% to $2.80-$3.10 due to acquisition-related charges, raising concerns about overall profitability.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval September 28, 2023).

POMBILITI cipaglucosidase alfa Updated Nov 2

What to watch

Pombiliti is already approved and commercializing, so the next catalysts are commercial execution metrics in BioMarin's quarterly earnings reports and any potential label expansion. Watch for Q3 2026 Pombiliti+Opfolda revenue contribution when BioMarin reports earnings on November 2, 2026 (today), and monitor Sanofi's Nexviazyme competitive moves including its potential infantile-onset Pompe label expansion.

Bull case
  • Pombiliti+Opfolda generated $112.5M in 2025 sales, growing 60% year-over-year, indicating strong commercial uptake
  • BioMarin's global commercial infrastructure can expand Pombiliti access to new markets, as stated in the Amicus acquisition rationale
  • Five-year Phase 3 extension data presented October 2026 showed durable efficacy with no new safety signals, supporting long-term use
Bear case
  • Sanofi's Nexviazyme has a broader label covering patients aged 1 year and older, versus Pombiliti's narrower indication for adults >=40kg not improving on current ERT
  • Sanofi reported positive Phase 3 data for Nexviazyme in infantile-onset Pompe in June 2026 and plans to seek label expansion
  • Pombiliti is a small part of BioMarin's overall revenue; BioMarin cut full-year 2026 EPS guidance on other pipeline charges, signaling broader company challenges
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since February 2014.

VIMIZIM elosulfase alfa Updated Nov 2

What to watch

VIMIZIM is a mature, approved revenue driver with no binary catalyst ahead. Watch for any biosimilar entry (projected exclusivity loss around 2026-2029) and for quarterly revenue trends in BioMarin's Metabolic Conditions segment, which includes VIMIZIM alongside newer acquired assets. The next major BioMarin catalyst is the VOXZOGO PDUFA for hypochondroplasia on May 30, 2027, not VIMIZIM.

Bull case
  • VIMIZIM is the first and only FDA-approved enzyme replacement therapy for Morquio A syndrome (MPS IVA), with no approved competitor, giving it a durable market position.
  • BioMarin's Q3 2026 earnings reported Metabolic Conditions revenue (which includes VIMIZIM) grew 44% Y/Y, with higher VIMIZIM revenue cited as a contributor, and patient numbers increased across all Metabolic Conditions therapies.
  • VIMIZIM generated approximately $740M in net product revenue in 2024 (per BioMarin's 10-K), making it one of the company's top three products and a significant cash flow contributor.
Bear case
  • Orphan drug exclusivity expired in 2021; projected loss of broader exclusivity around February 2026 (per CliffBio's 12-year biologic estimate), opening the door to eventual biosimilar competition.
  • VIMIZIM revenue can be lumpy due to timing of large government orders outside the U.S., as noted in BioMarin's Q2 2026 earnings release.
  • BioMarin's Q3 2026 earnings (Nov 2, 2026) showed a GAAP net loss of -$123M and a ~40% cut to full-year Non-GAAP EPS guidance, driven by acquisition-related charges, creating headline risk for the whole portfolio.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2003.

ALDURAZYME laronidase Updated Nov 2

What to watch

ALDURAZYME has no upcoming PDUFA dates, pivotal readouts, or regulatory decisions. The next meaningful data point for this drug is routine quarterly revenue disclosures within BioMarin's earnings reports. For BioMarin stock, the far larger value drivers are VOXZOGO (achondroplasia) and the recently acquired Amicus Therapeutics portfolio. ALDURAZYME is not a catalyst for BMRN shares.

Bull case
  • ALDURAZYME generated $208.5 million in revenue in 2025, up 13.4% year-over-year, showing steady growth in a well-established rare-disease market.
  • No approved U.S. biosimilar exists, and manufacturing complexity plus the small patient population create a high barrier to generic competition.
  • The drug treats a severe, life-limiting genetic disease with no alternative approved enzyme replacement therapy, providing a stable, recurring revenue stream.
Bear case
  • ALDURAZYME represents only about 6.5% of BioMarin's total revenue ($208.5M of $3.2B in 2025), making it a minor contributor with limited impact on the stock.
  • U.S. orphan-drug exclusivity expired in 2010, leaving the drug protected only by manufacturing complexity and biologic product profile, not regulatory barriers.
  • A biosimilar from Iran's CinnaGen has completed a Phase 3 crossover study, signaling eventual biosimilar competition that could erode pricing.
● neutral
Impact
PhasePhase 1/2
Time to marketIf Phase 1/2 data are positive, Phase 2/3 pivotal trials would likely take several more years; a potential FDA submission is likely 4-6 years away (late 2020s to early 2030s), assuming successful development.

BMN 450 long-acting recombinant alpha-galactosidase A Updated Nov 2

What to watch

Watch for initial safety and tolerability data from the ongoing Phase 1/2 study (NCT06858397) of BMN 450, which could read out in 2027. Positive data would validate the subcutaneous-dosing hypothesis and strengthen BioMarin's Fabry franchise; negative safety signals or lack of biomarker effect would undermine the thesis for this early-stage asset. The next hard catalyst is not yet dated.

Bull case
  • BMN 450 is designed as a once-monthly subcutaneous injection, which could be a meaningful convenience advantage over current IV ERTs (Fabrazyme, Elfabrio) that require bi-weekly 3-4 hour infusions at a clinic.
  • It is mutation-agnostic, meaning it could treat all Fabry patients regardless of genetic variant, expanding BioMarin's addressable Fabry population beyond the ~35-50% of patients with GALAFOLD-amenable mutations.
  • BioMarin now has a complete Fabry franchise: GALAFOLD (oral chaperone for amenable mutations) plus BMN 450 (subcutaneous ERT for all patients), creating potential for lifecycle management and market expansion.
Bear case
  • BMN 450 is in very early clinical development (Phase 1/2, 18-patient study) with no efficacy data yet; the vast majority of Phase 1/2 assets never reach approval.
  • The Fabry ERT market is already served by established IV products (Sanofi's Fabrazyme, Chiesi/Protalix's Elfabrio) that have decades of real-world data; a new entrant must prove superior convenience, safety or efficacy to switch patients.
  • BioMarin paid $70M upfront plus up to $405M in milestones and royalties, creating a high bar for return on investment if the drug fails or is commercially underwhelming.
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 ACTION 3 trial succeeds, a U.S. FDA submission could follow in 2028 or 2029, with potential approval in 2029-2030, assuming standard review timelines.

BMN 820 repagermanium Updated Nov 2

What to watch

The next catalyst for BMN 820 is the Phase 3 ACTION 3 topline data readout, expected in 2028. Positive data would validate the FSGS opportunity for BioMarin's U.S. commercialization rights, while a miss would effectively zero out the program's value. In the nearer term, watch for any Dimerix disclosures on trial progress or interim analyses. BMN 820 is a small part of a large, diversified pipeline at BioMarin, so even a binary outcome would likely move BMRN shares by mid-single-digit percentages, not a make-or-break swing.

Bull case
  • BMN 820 is a first-in-class oral CCR2 inhibitor addressing a high-unmet-need rare kidney disease with a U.S. addressable patient population of approximately 30,000.
  • The Phase 3 ACTION 3 trial is fully enrolled (286 patients) and passed a pre-specified interim efficacy analysis in March 2024, with an external blinded review confirming >90% statistical power.
  • BioMarin acquired the U.S. rights through its Amicus Therapeutics acquisition, adding a late-stage asset to its rare-disease portfolio without upfront clinical risk.
Bear case
  • The Phase 3 ACTION 3 trial is run by Dimerix, not BioMarin, and BioMarin only holds U.S. commercialization rights, limiting upside capture. Dimerix operates the trial and controls the data timeline.
  • Travere Therapeutics' FILSPARI (sparsentan) was approved by the FDA for FSGS in April 2026, establishing a first-in-class approved competitor that could limit BMN 820's market opportunity.
  • FSGS is a heterogeneous disease with a history of clinical trial failures, making Phase 3 success uncertain despite positive Phase 2 data.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since December 2007.

KUVAN sapropterin dihydrochloride Updated Nov 2

What to watch

KUVAN has no upcoming regulatory catalysts or pivotal readouts; it is a mature, declining product facing generic erosion. For BioMarin investors, the focus should remain on VOXZOGO's growth trajectory, the integration of the Amicus acquisition (GALAFOLD, POMBILITI+OPFOLDA), and the PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia. KUVAN itself is not a stock-moving catalyst.

Bull case
  • KUVAN was the first FDA-approved drug for PKU and remains a recognized brand with established prescribing patterns among metabolic disease specialists.
  • BioMarin continues to support KUVAN with patient access programs, and the drug still generates positive cash flow even with generic competition.
  • The latest FDA-listed patent extends to May 2033, providing some theoretical long-tail exclusivity protection for certain formulations.
Bear case
  • Generic competition is well-established: Camber Pharmaceuticals launched a generic in January 2023, and there are now 8 approved generic makers in the FDA Orange Book, eroding KUVAN's market share and pricing power.
  • KUVAN revenue is in structural decline: Q3 2026 revenue was $23 million (down 4% YoY), and full-year 2025 KUVAN sales declined 18% due to generic pressure.
  • KUVAN now represents only about 2% of BioMarin's total quarterly revenue, making it immaterial to the company's overall financial performance and investment thesis.
● neutral
Impact
PhasePhase 1/2
Time to marketAt least 4-6 years away. The drug is in Phase 1/2 with no pivotal trial yet initiated. If the year-end 2026 update is positive, a Phase 3 trial could start in 2027-2028, with potential approval in the 2030-2032 timeframe, assuming success.

BMN 351 nivudirsen Updated Nov 2

What to watch

Watch for BioMarin's year-end 2026 program update on BMN 351, which is expected to include clinical data from the 6 mg/kg and 9 mg/kg cohorts of the Phase 1/2 study. Positive dystrophin expression data could support advancement to a pivotal trial, while any safety signal or disappointing efficacy would be a setback. However, given BMN 351's small weight in BioMarin's diversified portfolio, even a clear outcome is unlikely to move the stock more than a few percent.

Bull case
  • BMN 351 targets a novel binding site in exon 51 and produces near-full-length dystrophin (similar to the milder Becker form of MD), which may offer a functional advantage over the truncated dystrophin from eteplirsen.
  • Initial Phase 1/2 data showed 5.0% mean absolute dystrophin expression at week 25 in the 9 mg/kg cohort with acceptable safety, and PK/PD modeling predicts dystrophin levels will continue to rise toward steady state.
  • Sarepta's next-gen exon 51 candidate SRP-5051 was discontinued, leaving a potential opening for BMN 351 as a potentially improved therapy in this genetic subpopulation (~13% of DMD patients).
Bear case
  • BMN 351 is still in early Phase 1/2 with limited patient data; the 5.0% mean absolute dystrophin expression at week 25 is modest and may not translate into meaningful functional improvement.
  • Sarepta's Exondys 51 (eteplirsen) is already FDA-approved for exon 51 skip-amenable DMD, giving it a major commercial head start and real-world safety track record.
  • The DMD exon 51 skipping field has seen setbacks: Sarepta discontinued its next-gen SRP-5051 in 2024 due to safety concerns (hypomagnesemia, kidney issues), highlighting the regulatory risk for this mechanism.
● neutral
Impact
PhasePreclinical
Time to marketBMN 430 is at the preclinical stage, still working to identify a lead candidate. Assuming successful preclinical development, IND-enabling studies, and regulatory clearance, clinical trials would likely not begin before 2028 at the earliest. Commercialization, if successful, is many years away (likely 2030s).

BMN 430 Updated Nov 2

What to watch

BMN 430 has no hard dated catalyst in the next 12 months. The next milestone to watch is selection of a lead ASO candidate from preclinical studies, which could be announced in 2027. For BioMarin investors, the far more material near-term catalysts are the VOXZOGO hypochondroplasia PDUFA (target action date May 30, 2027) and commercial execution of the recently acquired Amicus portfolio (GALAFOLD, POMBILITI+OPFOLDA).

Bull case
  • First-in-disease potential: ReNU syndrome has no approved targeted therapies, and BMN 430 could be the first medicine for this newly identified condition (discovered 2024).
  • Large addressable rare disease: ReNU syndrome is described as the most common known autosomal dominant neurodevelopmental disorder, potentially affecting thousands of patients worldwide.
  • Precision targeting: The ASO targets the RNU4-2 (n.64_65insT) variant, which accounts for approximately 75% of ReNU syndrome cases, giving it a defined patient population.
Bear case
  • Very early stage: BMN 430 is still in preclinical studies working to identify a lead ASO candidate. Most preclinical drug candidates fail before reaching clinical trials.
  • No near-term catalysts: There is no scheduled PDUFA, clinical readout, or regulatory milestone for BMN 430 in the next 12 months, offering no near-term stock-moving events.
  • Dilution risk within BioMarin's pipeline: BMN 430 is one of several early pipeline additions (BMN 450, BMN 440, BMN 820) and is immaterial to BioMarin's near-term financial performance or valuation.
● neutral
Impact
PhasePhase 1/2a
Time to marketAt least 4-6 years, assuming successful Phase 1/2a data in 2027, followed by Phase 2b/3 trials and regulatory filing.

BMN 440 ale1 Updated Nov 2

What to watch

The next catalyst for BMN 440 is Phase 1/2a safety and pharmacodynamics data expected in 2027 (no specific month given). Positive data would validate the oral small-molecule approach in HPP and support advancement to later-stage trials, while any safety or efficacy signal issues would raise questions about the $275M Alesta acquisition. For now, the program is too early and too small relative to BioMarin's overall portfolio to be a standalone driver of the stock.

Bull case
  • BMN 440 is a potential first-in-class oral therapy for hypophosphatasia (HPP), which could offer a major convenience advantage over the current injected enzyme replacement therapy (Strensiq), potentially expanding the addressable patient population.
  • BioMarin's CEO stated that ALE1 has the potential to serve the company's largest addressable patient population, suggesting meaningful commercial opportunity if successful.
  • The HPP treatment market is estimated at roughly $1B+ and growing, with oral delivery representing a clear differentiation from injectable biologics.
Bear case
  • BMN 440 is in Phase 1/2a, the earliest stage of clinical testing, with no human efficacy data yet; first-in-human trials carry high failure risk.
  • The existing HPP standard of care, Strensiq (asfotase alfa, Alexion/AstraZeneca), is already approved and AstraZeneca's next-generation efzimfotase alfa received FDA Priority Review in September 2026 with a decision expected in early 2027, potentially narrowing the window for a new entrant.
  • BioMarin paid $275M upfront plus up to $215M in milestones for Alesta/ALE1, a significant bet on an unvalidated oral mechanism that targets a novel pathway (PPi reduction) rather than replacing the missing enzyme.
▼ bearish
Impact
PhaseApproved (FDA June 2023, EMA August 2022), then voluntarily withdrawn February 2026.
Time to marketWithdrawn from market as of February 2026; no longer commercially available.

ROCTAVIAN valoctocogene roxaparvovec Updated Nov 2

What to watch

ROCTAVIAN is a withdrawn drug with no remaining commercial presence or regulatory catalysts. BioMarin's stock thesis now rests entirely on VOXZOGO (achondroplasia), its enzyme replacement therapy portfolio, and the recently acquired Alesta Therapeutics pipeline. The Q3 2026 earnings beat (EPS $0.23 vs -$0.08 consensus) shows the company is moving past the ROCTAVIAN failure, but the drug itself is a closed chapter for investors.

Bull case
  • ROCTAVIAN was the first FDA-approved gene therapy for severe hemophilia A (June 29, 2023), a genuine scientific milestone that demonstrated durable hemostatic efficacy for 5+ years in Phase 3 GENEr8-1 trial data.
  • The withdrawal was voluntary and driven by commercial/reimbursement dynamics, not safety or efficacy concerns. The drug's clinical profile remained intact.
  • Removing ROCTAVIAN simplifies BioMarin's portfolio and removes a cash-burning commercial operation, allowing management to focus on higher-growth assets like VOXZOGO.
Bear case
  • ROCTAVIAN was a high-profile commercial failure: priced at $2.9 million per dose, it faced severe reimbursement hurdles and negligible uptake despite FDA approval.
  • BioMarin took roughly $240 million in charges (including a $119 million inventory write-off) in Q4 2025 related to the withdrawal, a direct hit to shareholders.
  • The drug's failure raises questions about the viability of one-time gene therapy business models, which may weigh on BioMarin's gene therapy pipeline efforts.

Other drugs in filings and trials

no drug report yet
  • VOXZOGO Next: PDUFA date · May 30, 2027 Last: NDA filed · Jun 30, 2026
  • INZ-701 1 trial
  • Vosoritide 1 trial
  • Vosoritide Injection 1 trial

Past FDA events & how the stock moved

8 events
DateDrugEvent1 day5 days
Jun 30, 2026VOXZOGONDA filed+0.3%+3.6%
Apr 1, 2026VOXZOGONDA filed−1.8%−0.3%
Feb 28, 2026PALYNZIQPDUFA decision−3.2%−1.0%
Nov 19, 2021VOXZOGOApproval+8.9%+5.4%
May 24, 2018PALYNZIQApproval+4.6%+3.9%
Apr 27, 2017BRINEURAApproval−0.2%+1.8%
Feb 14, 2014VIMIZIMApproval+0.6%+8.1%
Dec 19, 2013KUVANApproval+0.1%+0.7%

Clinical trials

5 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Vosoritide InjectionA Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentPhase 2Terminated18Sep 16, 2026
INZ-701ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 DeficiencyPhase 3Terminated2Aug 31, 2026
VosoritideInterventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPhase 3Completed81Apr 23, 2026
ROCTAVIANSafety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsPhase 2Completed10Apr 20, 2026
INZ-701The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 DeficiencyPhase 3Terminated27Jan 29, 2026